What is FemExcel?
FemExcel is a women's health telehealth platform built around a simple but important insight: weight loss in women is not just about calories and exercise. Hormonal fluctuations — particularly through perimenopause, menopause, and the years surrounding them — fundamentally change how a woman's body stores fat, processes insulin, responds to exercise, and regulates appetite.
Most generic weight loss programs, including many GLP-1 telehealth platforms, treat all patients the same regardless of gender or hormonal status. FemExcel is built specifically for women, staffed by providers with focused expertise in female hormonal health, and designs treatment plans that address the underlying hormonal picture alongside weight management strategies.
For women who have done everything "right" — tracked calories, exercised consistently, tried multiple programs — and still struggled to lose weight, a hormonal evaluation frequently reveals why.
Recognize yourself in that description?
FemExcel's intake evaluates all 6 key hormones and builds a plan around what's actually going on for you.
Start your FemExcel evaluation →The hormone-weight connection FemExcel addresses
Understanding why FemExcel's approach is different requires understanding how hormones affect weight in women. Here are the key hormonal factors the platform evaluates:
Estrogen
Declining estrogen during perimenopause shifts fat storage from the hips and thighs to the abdomen — the more metabolically dangerous visceral fat. It also affects insulin sensitivity and appetite regulation.
Progesterone
Low progesterone often accompanies estrogen decline and contributes to water retention, bloating, sleep disruption, and increased cortisol — all of which make weight loss harder.
Thyroid hormones
Hypothyroidism is significantly more common in women than men and directly slows metabolism. Many women go years with subclinical thyroid dysfunction that standard testing misses.
Cortisol
Chronic stress elevates cortisol, which promotes abdominal fat storage, increases appetite for calorie-dense foods, and disrupts sleep — creating a cycle that standard diet programs don't break.
DHEA
This adrenal precursor hormone feeds into the body's production of both estrogen and testosterone. Levels decline steadily with age, and low DHEA is linked to reduced energy, muscle mass, and metabolic rate.
Testosterone
Women need testosterone too — and low levels reduce muscle mass, energy, and metabolic rate. This is frequently overlooked in standard women's health evaluations.
How FemExcel works
FemExcel's process starts with a comprehensive evaluation rather than a generic intake questionnaire:
- Detailed health intake: More thorough than most telehealth platforms — covers menstrual history, menopausal status, symptoms, current medications, prior weight loss attempts, and lifestyle factors.
- Provider consultation: A licensed clinician with women's health expertise reviews your intake. Depending on your situation, they may recommend hormone testing before finalizing a treatment plan.
- Personalized treatment plan: Your plan may include hormone optimization, metabolic support, nutritional guidance, and lifestyle recommendations — tailored to your specific hormonal picture rather than a generic protocol.
- Ongoing monitoring: Regular follow-ups to assess progress, adjust the treatment plan, and manage any side effects or concerns.
What FemExcel treats
FemExcel's programs address a range of women's health and hormonal concerns that intersect with weight management:
- Perimenopause and menopause weight gain: The most common reason women seek out the platform — addressing the hormonal shifts driving abdominal fat accumulation in midlife
- Hormone optimization: Estrogen, progesterone, and testosterone balance for women whose levels are out of range
- Thyroid support: Evaluation and management of thyroid function as it relates to metabolism and weight
- Metabolic support: Addressing insulin resistance and metabolic factors that make weight loss harder than it should be
- General women's weight management: For women at any age who want a clinically supervised, hormone-aware approach to weight loss
Pricing
FemExcel pricing varies based on the treatment plan developed after your consultation. Expect programs to start around $79/month for foundational support, with more comprehensive hormone optimization programs running higher depending on the treatments prescribed and monitoring required.
This is comparable to or lower than many women's hormone telehealth platforms, particularly given the level of specialization and personalization involved. FemExcel does not accept standard insurance for most services. Check whether your HSA or FSA plan covers telehealth hormone therapy.
How FemExcel compares
| Feature | FemExcel | Alloy | Midi Health | Generic GLP-1 platform |
|---|---|---|---|---|
| Women-only focus | ✓ Yes | ✓ Yes | ✓ Yes | No |
| Hormone optimization | ✓ Full | ✓ Yes | ✓ Yes | Rarely |
| GLP-1 medication access | Limited | Limited | Limited | ✓ Primary focus |
| Thyroid evaluation | ✓ Yes | Limited | ✓ Yes | Rarely |
| Personalized treatment plan | ✓ Full | ✓ Yes | ✓ Yes | Generic |
| Starting price | ~$79/mo | ~$99/mo | ~$85/mo | ~$99/mo |
Who should use FemExcel
FemExcel is the right choice if you're a woman who has struggled to lose weight despite genuine effort and suspects hormonal factors may be involved, if you're in perimenopause or menopause and experiencing the characteristic weight redistribution to your abdomen, if you want a women's health specialist rather than a generalist reviewing your case, or if prior weight loss programs have failed you and you're ready to address the underlying biology.
If your primary goal is GLP-1 medication access and hormonal factors are less of a concern, DirectMeds or another GLP-1 telehealth platform may be a more direct route. The two approaches aren't mutually exclusive — some women benefit from both.
Side effects and safety
Hormone therapy carries its own risk profile that differs from GLP-1 medications. Potential risks associated with hormone replacement therapy include increased risk of blood clots, stroke, and certain hormone-sensitive cancers depending on the type of therapy, duration, and individual risk factors. These risks are highly individualized and depend significantly on your personal and family medical history.
FemExcel providers conduct thorough intake evaluations specifically to assess these risks before recommending any hormone therapy. This is not a platform that issues prescriptions without understanding your full health picture. As with all medical treatment decisions, discuss your individual risk profile carefully with your FemExcel provider.
See if FemExcel is right for you
The intake process is designed to identify whether hormonal factors are contributing to your weight challenges. Women-specific clinical expertise from the first consultation.
Start your FemExcel evaluation →Frequently asked questions
Our verdict
FemExcel addresses something that most weight loss programs completely ignore: the hormonal biology that makes weight loss disproportionately difficult for many women, particularly in midlife. For women who have tried and failed with standard approaches, a hormone-first evaluation frequently reveals why — and what to do about it.
It's not the right fit for everyone, and it's not a GLP-1 platform. But for women whose weight challenges have a hormonal root cause, FemExcel is one of the most thoughtful telehealth options we've evaluated.
Rating: 4.6/5 · Recommended for women seeking hormone-informed, personalized weight management support.
Start your FemExcel evaluation → Women only · Licensed provider consultation · Hormone therapy carries risks — discuss with your providerWhat the research shows on hormones and GLP-1 response
The connection between estrogen and GLP-1 efficacy is an active area of research. A Mayo Clinic study published in January 2026 in The Lancet Obstetrics, Gynaecology & Women's Health followed 120 postmenopausal women with overweight or obesity who had been on tirzepatide for 12 or more months. Those also using menopausal hormone therapy lost about 35% more weight than those on tirzepatide alone. Researchers, including senior author Dr. Maria Daniela Hurtado Andrade, were careful to note this was an observational study, not a randomized trial — it shows a link, not proof that hormone therapy caused the extra weight loss. Lead author Dr. Regina Castaneda has pointed to preclinical data suggesting estrogen may enhance GLP-1's appetite-suppressing effects as one possible mechanism, with confirmatory randomized trials still needed.
Progesterone also plays a role: low progesterone is independently associated with increased cortisol, which drives abdominal fat accumulation and insulin resistance — both of which can work against weight loss on any intervention. The practical takeaway for women in hormonal transition is that optimizing the hormonal environment alongside a GLP-1 medication is a promising area worth discussing with a provider, even though the evidence connecting the two is still early.
For the fuller breakdown of this research — including a second, independent study that found the same pattern with semaglutide — see our complete guide to choosing the best GLP-1 for menopause weight loss.
What FemExcel evaluates — the full hormone panel
FemExcel evaluates all six key hormones rather than a single-marker approach:
- Estradiol (E2) — the primary active estrogen; low levels are directly associated with reduced GLP-1 receptor expression and increased abdominal fat
- Progesterone — low progesterone raises cortisol and drives insulin resistance; often the first hormone to decline in perimenopause
- Testosterone — yes, in women too: low testosterone in women is associated with reduced muscle mass, fatigue, and reduced libido, all of which affect body composition and adherence to lifestyle changes
- DHEA — precursor hormone that affects energy and body composition; declines with age in both men and women
- Cortisol — chronic elevation drives abdominal weight gain, suppresses thyroid function, and interferes with GLP-1 response
- Thyroid (TSH/T3/T4) — hypothyroidism is an independent cause of weight resistance and hair loss that frequently overlaps with the symptoms women attribute to perimenopause or GLP-1 side effects
Who benefits most from combining FemExcel with a GLP-1 medication
Based on the available research and the clinical profile FemExcel targets, the women most likely to see meaningful incremental benefit from addressing hormones alongside GLP-1 treatment are:
- Women 40+ experiencing perimenopause symptoms (irregular cycles, hot flashes, sleep disruption, mood changes) alongside weight resistance
- Women with GLP-1 medications who are losing less than expected given their adherence and protein intake
- Women experiencing significant hair loss on GLP-1 medications — low estrogen and low ferritin are both independent triggers for telogen effluvium that compound GLP-1-related hair shedding
- Women with documented low thyroid function or unexplained fatigue alongside weight resistance
Sources & references
- Castaneda R, Hurtado Andrade MD, et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. The Lancet Obstetrics, Gynaecology & Women's Health. January 2026. ScienceDirect — Observational cohort of 120 postmenopausal women on tirzepatide 12+ months; hormone therapy group lost ~35% more weight. Not a randomized trial; does not establish causation.
- Davis SR, et al. Testosterone for women: The clinical significance of androgen deficiency. J Clin Endocrinol Metab. 2019;104(10):4421–4429. PMID:31127303 — Testosterone deficiency in women: clinical presentation and treatment considerations.
- Kang D-H, et al. Telogen Effluvium Associated With Weight Loss. Ann Dermatol. 2024;36(6):384–388. PMC11621640 — Women and older adults particularly vulnerable to weight-loss-induced hair shedding; estrogen and ferritin as compounding factors.
- Sehgal NKR, et al. Self-reported side effects of semaglutide and tirzepatide in online communities. Nature Health. 2026. doi:10.1038/s44360-026-00108-y — Menstrual irregularities reported in nearly 4% of users; higher in female-only populations; temperature dysregulation as underreported GLP-1 effect.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMoa2032183 — STEP-1 trial: reference for semaglutide clinical outcomes cited in FemExcel review context.
Medical disclaimer: Informational only. Not medical advice. Consult a licensed physician before starting any medication.